Medical consumables | 'Ultra-low bid', this is the rhythm of going to finish

According to a report from the medical website on March 12th, low-cost winning bids are in line with the interests of the government, bidders, businesses and patients. But this road may be a dead end. Many low-cost medicines have disappeared from the market and are living examples. The price consumables won the bid and it is very likely that the mistake will be repeated.

From drug Industry precedents, refused to supply continuously.

In February 2018, 13 drugs in Liaoning were investigated for lack of supply;

In January 2018, Ningxia listed 49 lists of shortage drugs.

In December 2017, 33 drugs in Shanxi were rejected due to lack of profit.

In December 2017, 12 drugs in Gansu were rejected for cost increase.

In December 2017, Jiangxi interviewed 26 drug companies, mainly because the company's insufficient profit distribution ratio was too low.

In November 2017, there were 49 shortages of drugs in Liaoning. Both drugs were listed as bad records due to lack of supply.

In December 2017, during his inspection tour in Hubei, Premier Li expressed that there is no shortage of 'life-saving medicine' in the absence of anything.

The pharmaceutical industry has already been like this. Are medical equipments going to the same low-priced, low-cost routes?

From the perspective of the production companies, since last year, many places have begun to expose, in order to control the need for expenses, the hospital has successively dealt with the medical consumables in pain, and the price cuts are not in place. On the supply side, they may be unable to make ends meet; if not, they will go straight out. After a major price reduction, the production companies are not motivated to go back to the market.

From proxy From a business perspective, agents are porters, who move 30 dollars, and move 15 dollars, all of which are the same products. They face the same director of the hospital. Why did he move 15 blocks instead of moving 30 blocks? Of course, the move of 30 blocks may be too sharp, and it is very easy to be hit. It would be $25 in the bidding. This may be a mainstream model.

From the patient's point of view, there are almost no patents in the pharmaceutical industry. All of them are generic drugs. But in the field of medical consumables, everyone talks about patents because everyone has patents. Therefore, one product quits because of low prices. The market, which may not have succeeded, is also a harm to the patient.

As a result, products with low bid prices are kicked out of the market and eliminated. Naturally, if companies continue to tolerate attempting to 'monopolize the market' at prices below cost, this may be a rhythm of death.

The author believes that whether it is medicine or medical instruments , a multinational product enterprise Compared with the products, the quality is very different in many cases. The drug regulatory approval of the listing, can be produced, can only be considered qualified products. The tender party can not justify themselves for this reason.

For an industry to be developed and science and technology to be improved, there is no doubt that it needs funds to promote it. If it cannot guarantee a certain profit, then the development of the industry will not be able to talk about it.

'It's expensive to see a doctor, it's difficult to see a doctor'. This is a historic big problem. The main contradiction in solving this medical reform must be medical care. medicine , Medicare's three doctors linkage, this is also the national level has been working hard to advance.

In some localities, tenders are cut across the board. As for the lack of products, the quality of the winning bids is generally declining. The doctors dare to use them, and the patients dare to use them. Can they be used? That is not what he considered.

In the long run, ultra-low-cost medical consumables will surely be eliminated and the distance will not be far behind.